Pharmaceutical large Johnson & Johnson on Thursday filed for emergency authorization of its one-dose COVID-19 vaccine.
The corporate’s inoculation is 66 p.c efficient in opposition to average to extreme instances of the lethal international pandemic, nevertheless it solely requires a single dose and affords sturdy safety in opposition to hospitalization and dying from the bug, Politico reported.
The J&J vaccine would add an important third choice — together with Pfizer and Moderna photographs — because the US struggles to distribute vaccines in opposition to the coronavirus, which has killed greater than 455,000 People, in keeping with Johns Hopkins College, which is monitoring the virus.
Nonetheless, the J&J model has proved much less efficient in opposition to a extra aggressive pressure of the virus present in South Africa, the report stated.
That pressure, in addition to a variant recognized within the UK, has been detected within the US.
Nonetheless, the J&J vaccine offers a 3rd line of protection.
“Upon authorization of our investigational COVID-19 vaccine for emergency use, we’re prepared to start delivery,” Paul Stoffels, the corporate’s chief scientific officer, stated in an announcement. “We’re working with nice urgency to make our investigational vaccine out there to the general public as shortly as attainable.”